DE69735421T2 - Gegen inaktivierung resistenter faktor viii - Google Patents

Gegen inaktivierung resistenter faktor viii Download PDF

Info

Publication number
DE69735421T2
DE69735421T2 DE69735421T DE69735421T DE69735421T2 DE 69735421 T2 DE69735421 T2 DE 69735421T2 DE 69735421 T DE69735421 T DE 69735421T DE 69735421 T DE69735421 T DE 69735421T DE 69735421 T2 DE69735421 T2 DE 69735421T2
Authority
DE
Germany
Prior art keywords
fviii
protein
apc
nucleic acid
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69735421T
Other languages
German (de)
English (en)
Other versions
DE69735421D1 (de
Inventor
J. Randal Ann Arbor KAUFMAN
W. Steven Ypsilanti PIPE
Kagehiro Ann Arbor AMANO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
University of Michigan Ann Arbor
Original Assignee
University of Michigan System
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System, University of Michigan Ann Arbor filed Critical University of Michigan System
Publication of DE69735421D1 publication Critical patent/DE69735421D1/de
Application granted granted Critical
Publication of DE69735421T2 publication Critical patent/DE69735421T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69735421T 1996-04-24 1997-04-24 Gegen inaktivierung resistenter faktor viii Expired - Lifetime DE69735421T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1611796P 1996-04-24 1996-04-24
US16117P 1996-04-24
US1778596P 1996-05-15 1996-05-15
US17785P 1996-05-15
PCT/US1997/006563 WO1997040145A1 (en) 1996-04-24 1997-04-24 Inactivation resistant factor viii

Publications (2)

Publication Number Publication Date
DE69735421D1 DE69735421D1 (de) 2006-05-04
DE69735421T2 true DE69735421T2 (de) 2006-10-19

Family

ID=26688196

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69735421T Expired - Lifetime DE69735421T2 (de) 1996-04-24 1997-04-24 Gegen inaktivierung resistenter faktor viii
DE69740154T Expired - Lifetime DE69740154D1 (de) 1996-04-24 1997-04-24 Gegen Inaktivierung resistenter Faktor VIII

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69740154T Expired - Lifetime DE69740154D1 (de) 1996-04-24 1997-04-24 Gegen Inaktivierung resistenter Faktor VIII

Country Status (10)

Country Link
US (2) US6838437B2 (cg-RX-API-DMAC7.html)
EP (3) EP0910628B1 (cg-RX-API-DMAC7.html)
JP (2) JP3987114B2 (cg-RX-API-DMAC7.html)
AT (2) ATE502958T1 (cg-RX-API-DMAC7.html)
AU (1) AU3202797A (cg-RX-API-DMAC7.html)
CA (1) CA2252896C (cg-RX-API-DMAC7.html)
DE (2) DE69735421T2 (cg-RX-API-DMAC7.html)
DK (1) DK1754718T3 (cg-RX-API-DMAC7.html)
PT (1) PT1754718E (cg-RX-API-DMAC7.html)
WO (1) WO1997040145A1 (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0833848B1 (en) * 1995-06-12 2001-09-12 Stichting Sanquin Bloedvoorziening Factor ix binding peptides, derived from factor viii and their use as inhibitors of blood coagulation
US20040092442A1 (en) * 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
JP3987114B2 (ja) 1996-04-24 2007-10-03 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 不活性化耐性第▲８▼因子
AU3289599A (en) * 1998-02-13 1999-08-30 Cadus Pharmaceutical Corporation Mekk1 proteins and fragments thereof for use in regulating apoptosis
WO2002060951A2 (en) * 2001-01-12 2002-08-08 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
WO2003100053A1 (en) * 2002-05-22 2003-12-04 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of hemophilia a
US7041635B2 (en) * 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP1502921A1 (en) * 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
ES2395544T3 (es) 2004-12-23 2013-02-13 Novo Nordisk Health Care Ag Reducción del contenido de contaminantes proteínicos en composiciones que comprenden una proteína dependiente de la vitamina K de interés
WO2006108590A1 (en) * 2005-04-14 2006-10-19 Csl Behring Gmbh Modified coagulation factor viii with enhanced stability and its derivates
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP2520586A1 (en) * 2006-06-30 2012-11-07 The Regents of the University of Michigan Method of producing factor VIII proteins by recombinant methods
US20090203077A1 (en) * 2006-06-30 2009-08-13 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
KR101542752B1 (ko) 2006-12-22 2015-08-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 변형된 응고 인자
DK2865760T3 (en) 2008-06-24 2018-01-15 Csl Behring Gmbh Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
JP5922141B2 (ja) * 2010-11-05 2016-05-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 増加した比活性を有する抗血友病第ｖｉｉｉ因子の新規変異体
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
DK2768522T3 (en) 2011-10-18 2016-11-14 Csl Behring Gmbh The use of sulfated glycosaminoglycan for improving the bioavailability of blood coagulation factors.
EP2768521B1 (en) 2011-10-18 2016-07-13 CSL Behring GmbH Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii
EP2768853A1 (en) 2011-10-18 2014-08-27 CSL Limited Method for improving the stability of purified factor viii after reconstitution
ES2651523T3 (es) 2012-02-15 2018-01-26 Csl Behring Gmbh Variantes del Factor de von Willebrand que tienen afinidad de unión al Factor VIII mejorada
WO2014041500A2 (en) * 2012-09-12 2014-03-20 Centre For Bioseparation Technology-Vit Double mutant coagulation factor viii and methods thereof
KR20150088853A (ko) 2012-11-29 2015-08-03 바이엘 헬스케어 엘엘씨 활성화 단백질 c에 대한 인간화 모노클로날 항체 및 그의 용도
CA2892750A1 (en) * 2012-11-29 2014-06-05 Bayer Healthcare Llc Monoclonal antibodies agaisnt activated protein c (apc)
EP2988758B1 (en) * 2013-03-15 2018-04-25 Bayer HealthCare LLC Variant factor viii polypeptides and methods of their production and use
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
WO2015132724A1 (en) 2014-03-05 2015-09-11 Pfizer Inc. Improved muteins of clotting factor viii
JP6676551B2 (ja) 2014-07-02 2020-04-08 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 改変フォンウィルブランド因子
ES2772933T3 (es) 2015-03-06 2020-07-08 CSL Behring Lengnau AG Factor de von Willebrand modificado que tiene una semivida mejorada
JP6704420B2 (ja) * 2015-03-06 2020-06-03 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト フォンヴィレブランド因子の半減期を改善するための化合物
US10772936B2 (en) 2015-05-22 2020-09-15 CSL Behring Lengnau AG Methods for preparing modified von Willebrand factor
SG10201910896UA (en) 2015-05-22 2020-01-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
ES2909573T3 (es) 2016-01-07 2022-05-09 CSL Behring Lengnau AG Factor de von Willebrand truncado mutado
RU2018128613A (ru) 2016-01-07 2020-02-07 Цсл Беринг Ленгнау Аг Мутированный фактор фон виллебранда
SG11201903950UA (en) 2016-11-11 2019-05-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
DK3538134T3 (da) 2016-11-11 2022-02-07 CSL Behring Lengnau AG Trunkeret von willebrand-faktor polypeptider til ekstravaskulær administration til behandling eller profylakse af en blodkoagulationsforstyrrelse
CN120865384A (zh) * 2018-10-23 2025-10-31 费城儿童医院 用于调节因子viii功能的组合物和方法
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
AU2020395323A1 (en) * 2019-12-06 2022-06-30 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor VIII function

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214033A (en) * 1983-03-31 1993-05-25 Scripps Clinic & Research Foundation Factor VIII coagulant polypeptides
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US5045455A (en) * 1984-01-12 1991-09-03 Chiron Corporation Factor VIII:C cDNA cloning and expression
SE8501050D0 (sv) 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
EP0218712B1 (en) 1985-04-12 1992-02-26 Genetics Institute, Inc. Novel procoagulant proteins
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
DE3785102T2 (de) 1986-01-03 1993-07-22 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
AT388079B (de) 1986-04-18 1989-04-25 Helmut Ing Koenig Backofen
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
CA2068728A1 (en) 1989-11-17 1991-05-18 Barbara Chapman Protein complexes having factor viii:c activity and production thereof
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5563045A (en) * 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
WO1997003194A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Lysine 1689 factor viii:c polypeptide analogs
AU6486196A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
JP3987114B2 (ja) * 1996-04-24 2007-10-03 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 不活性化耐性第▲８▼因子

Also Published As

Publication number Publication date
ATE502958T1 (de) 2011-04-15
JP4250661B2 (ja) 2009-04-08
JP2007228973A (ja) 2007-09-13
ATE319817T1 (de) 2006-03-15
JP2000511407A (ja) 2000-09-05
US20060014683A1 (en) 2006-01-19
JP3987114B2 (ja) 2007-10-03
US6838437B2 (en) 2005-01-04
PT1754718E (pt) 2011-07-13
EP1754718A3 (en) 2007-05-16
US20020132306A1 (en) 2002-09-19
EP0910628A1 (en) 1999-04-28
EP0910628B1 (en) 2006-03-08
EP0910628A4 (en) 2001-05-02
EP2202242A1 (en) 2010-06-30
CA2252896A1 (en) 1997-10-30
EP1754718B1 (en) 2011-03-23
CA2252896C (en) 2009-03-10
DE69735421D1 (de) 2006-05-04
AU3202797A (en) 1997-11-12
EP1754718A2 (en) 2007-02-21
US7459534B2 (en) 2008-12-02
DE69740154D1 (de) 2011-05-05
WO1997040145A1 (en) 1997-10-30
DK1754718T3 (da) 2011-07-18

Similar Documents

Publication Publication Date Title
DE69735421T2 (de) Gegen inaktivierung resistenter faktor viii
DE69032600T3 (de) Rekombinanter abkömmling des menschlichen faktors iii
DE60133541T2 (de) Modifizierter faktor viii
DE60019122T2 (de) Veränderter faktor viii
DE69427997T2 (de) Hybrider mensch/tier faktor viii
DE69736068T2 (de) Faktor viii vom schwein und hybride davon
DE69126205T2 (de) Oxidationsresistente analoga des thrombomodulins
WO1997040145A9 (en) Inactivation resistant factor viii
EP1129186B2 (de) Ein faktor viii-polypeptid mit faktor viii:c-aktivität
DE69032043T2 (de) Proteinkomplexe mit faktor viii:c-aktivität und deren herstellung
US20120190623A1 (en) Inactivation Resistant Factor VIII
WO2003087355A1 (en) Inactivation resistant factor viii
DE69333738T2 (de) Therapeutische domänen des von willebrand-faktor
DE69333491T2 (de) Protease-Resistant Thrombomodulin Analogs
DE69132889T2 (de) Überlegende thrombomodulinanaloga zur pharmazeutischen verwendung
HK1019449B (en) A recombinant human factor viii derivative
HK1050537A (en) A recombinant human factor viii derivative
HK1009290B (en) A recombinant human factor viii derivative

Legal Events

Date Code Title Description
8364 No opposition during term of opposition